OBJECTIVE: To evaluate rheumatoid arthritis (RA) and mortality risk among women followed prospectively in the Nurses' Health Study (NHS). METHODS: We analyzed 119,209 women in the NHS who reported no connective tissue disease at enrollment in 1976. Comorbidity and lifestyle data were collected through biennial questionnaires. Incident RA cases were validated by medical records review. Cause of death was determined by death certificate and medical records review. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause, cardiovascular disease (CVD), cancer, and respiratory disease mortality for women with RA compared to those without RA. RESULTS: We validated 964 incident RA cases and identified 28,808 deaths during 36 years of prospective follow-up. Of 307 deaths among women with RA, 80 (26%) were from cancer, 70 (23%) were from CVD, and 44 (14%) were from respiratory causes. Women with RA had increased total mortality (HR 1.40, 95% CI 1.25-1.57) compared to those without RA, independent of mortality risk factors, including smoking. RA was associated with significantly increased respiratory disease mortality (HR 2.06, 95% CI 1.51-2.80) and cardiovascular disease mortality (HR 1.45, 95% CI 1.14-1.83), but not cancer mortality (HR 0.93, 95% CI 0.74-1.15). For women with seropositive RA, respiratory disease mortality was nearly 3-fold higher than among non-RA women (HR 2.67, 95% CI 1.89-3.77). CONCLUSION: Women with RA had significantly increased mortality compared to those without RA. Respiratory disease and cardiovascular disease mortality were both significantly elevated for women with RA. The nearly 3-fold increased relative risk of respiratory disease mortality was observed only for those with seropositive RA.
OBJECTIVE: To evaluate rheumatoid arthritis (RA) and mortality risk among women followed prospectively in the Nurses' Health Study (NHS). METHODS: We analyzed 119,209 women in the NHS who reported no connective tissue disease at enrollment in 1976. Comorbidity and lifestyle data were collected through biennial questionnaires. Incident RA cases were validated by medical records review. Cause of death was determined by death certificate and medical records review. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause, cardiovascular disease (CVD), cancer, and respiratory disease mortality for women with RA compared to those without RA. RESULTS: We validated 964 incident RA cases and identified 28,808 deaths during 36 years of prospective follow-up. Of 307 deaths among women with RA, 80 (26%) were from cancer, 70 (23%) were from CVD, and 44 (14%) were from respiratory causes. Women with RA had increased total mortality (HR 1.40, 95% CI 1.25-1.57) compared to those without RA, independent of mortality risk factors, including smoking. RA was associated with significantly increased respiratory disease mortality (HR 2.06, 95% CI 1.51-2.80) and cardiovascular disease mortality (HR 1.45, 95% CI 1.14-1.83), but not cancer mortality (HR 0.93, 95% CI 0.74-1.15). For women with seropositive RA, respiratory disease mortality was nearly 3-fold higher than among non-RA women (HR 2.67, 95% CI 1.89-3.77). CONCLUSION:Women with RA had significantly increased mortality compared to those without RA. Respiratory disease and cardiovascular disease mortality were both significantly elevated for women with RA. The nearly 3-fold increased relative risk of respiratory disease mortality was observed only for those with seropositive RA.
Authors: B J Radovits; J Fransen; S Al Shamma; A M Eijsbouts; P L C M van Riel; R F J M Laan Journal: Arthritis Care Res (Hoboken) Date: 2010-03 Impact factor: 4.794
Authors: An Pan; Qi Sun; Adam M Bernstein; Matthias B Schulze; JoAnn E Manson; Meir J Stampfer; Walter C Willett; Frank B Hu Journal: Arch Intern Med Date: 2012-03-12
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Richard D Bell; Emily K Wu; Christopher A Rudmann; Megan Forney; Claire R W Kaiser; Ronald W Wood; Joe V Chakkalakal; Nicole D Paris; Alanna Klose; Guang-Qian Xiao; Javier Rangel-Moreno; Maria L Garcia-Hernandez; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Jürgen Braun; Klaus Krüger; Bernhard Manger; Matthias Schneider; Christof Specker; Hans Joachim Trappe Journal: Dtsch Arztebl Int Date: 2017-03-24 Impact factor: 5.594
Authors: H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks Journal: Expert Rev Clin Immunol Date: 2020-01-06 Impact factor: 4.473
Authors: Elena Myasoedova; Sherine E Gabriel; Eric L Matteson; John M Davis; Terry M Therneau; Cynthia S Crowson Journal: J Rheumatol Date: 2017-04-01 Impact factor: 4.666
Authors: Jeffrey A Sparks; Tzu-Chieh Lin; Carlos A Camargo; Medha Barbhaiya; Sara K Tedeschi; Karen H Costenbader; Benjamin A Raby; Hyon K Choi; Elizabeth W Karlson Journal: Semin Arthritis Rheum Date: 2017-09-18 Impact factor: 5.532
Authors: Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Curr Rheumatol Rev Date: 2019